dapansutrile-pd-nct07157735

Dapansutrile (OLT1177) for Parkinson's Disease (NCT07157735)

Trial Overview

| Field | Value |
|-------|-------|
| NCT Number | NCT07157735 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Olatec Therapeutics |
| Intervention | Dapansutrile (OLT1177) |
| Mechanism | NLRP3 inflammasome inhibitor |
| Route | Oral |
| Study Design | Randomized, double-blind, placebo-controlled |

Introduction and Clinical Significance

Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide[@kalia2015]. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the hallmark motor symptoms including bradykinesia, resting tremor, rigidity, and postural instability. Additionally, non-motor symptoms such as cognitive impairment, depression, sleep disorders, and autonomic dysfunction significantly impact quality of life[@bloem2021].

Despite decades of research, current treatments remain primarily symptomatic, focusing on dopamine replacement therapy with levodopa and dopamine agonists. While these interventions provide substantial benefit, they do not halt or slow disease progression. The development of disease-modifying therapies remains an urgent unmet need[@jankovic2020].

Dapansutrile (OLT1177) for Parkinson's Disease (NCT07157735)

Trial Overview

| Field | Value |
|-------|-------|
| NCT Number | NCT07157735 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Olatec Therapeutics |
| Intervention | Dapansutrile (OLT1177) |
| Mechanism | NLRP3 inflammasome inhibitor |
| Route | Oral |
| Study Design | Randomized, double-blind, placebo-controlled |

Introduction and Clinical Significance

Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide[@kalia2015]. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the hallmark motor symptoms including bradykinesia, resting tremor, rigidity, and postural instability. Additionally, non-motor symptoms such as cognitive impairment, depression, sleep disorders, and autonomic dysfunction significantly impact quality of life[@bloem2021].

Despite decades of research, current treatments remain primarily symptomatic, focusing on dopamine replacement therapy with levodopa and dopamine agonists. While these interventions provide substantial benefit, they do not halt or slow disease progression. The development of disease-modifying therapies remains an urgent unmet need[@jankovic2020].

Neuroinflammation has emerged as a critical driver of PD pathogenesis. The NLRP3 (NLR Family Pyrin Domain Containing 3) inflammasome plays a central role in chronic neuroinflammation observed in Parkinson's disease. This intracellular protein complex activates caspase-1, leading to the production of pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18), as well as the initiation of pyroptosis, a form of inflammatory cell death[@zhou2021].

In PD, microglial NLRP3 is chronically activated by α-synuclein aggregates, mitochondrial dysfunction, and environmental toxins. This activation creates a self-perpetuating cycle of neuroinflammation that drives dopaminergic neuron loss. Studies have demonstrated elevated NLRP3 activation and increased IL-1β levels in the substantia nigra and cerebrospinal fluid of PD patients[@haque2019].

Drug Profile: Dapansutrile (OLT1177)

Mechanism of Action

Dapansutrile (also known as OLT1177) is a novel, selective NLRP3 inflammasome inhibitor developed by Olatec Therapeutics. Unlike broad-spectrum anti-inflammatory drugs, dapansutrile offers targeted inhibition of this specific inflammatory pathway[@marchetti2018].

The molecular mechanism involves:

Pharmacological Properties

Dapansutrile has demonstrated favorable pharmacological properties in preclinical and clinical studies:

• Oral bioavailability: Well-absorbed following oral administration
• Safety profile: Demonstrated acceptable tolerability in Phase 1 and Phase 2 trials for inflammatory conditions
• Anti-inflammatory efficacy: Significant reduction in IL-1β and IL-18 production
• Brain penetration: Evidence of central nervous system activity in preclinical models[@yan2021]

Preclinical Evidence in Parkinson's Disease

MPTP Model Studies

The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model is a well-established preclinical model of PD. Studies with dapansutrile have demonstrated significant neuroprotective effects[@liang2020]:

• Dopaminergic neuron preservation: Dapansutrile treatment significantly reduced loss of tyrosine hydroxylase-positive neurons in the substantia nigra
• Motor function improvement: Treated animals showed improved performance in behavioral tests including rotarod and cylinder tests
• Inflammation reduction: Decreased microglial activation and reduced pro-inflammatory cytokine expression
• α-synuclein mitigation: Reduced α-synuclein aggregation in the substantia nigra

6-OHDA Model Studies

The 6-hydroxydopamine (6-OHDA) model provides complementary evidence for dapansutrile's neuroprotective effects[@yan2020]:

• Neuroprotection: Preservation of dopaminergic neurons following 6-OHDA lesion
• Behavioral recovery: Improved apomorphine-induced rotational behavior
• Anti-inflammatory effects: Reduced NLRP3 activation and IL-1β production

Mechanism Validation

Preclinical studies have established that dapansutrile's neuroprotective effects are mediated through NLRP3 inhibition[@greaney2022]:

Clinical Development Timeline

Phase 1 Studies

Dapansutrile has undergone extensive Phase 1 evaluation demonstrating:

• Safety and tolerability in healthy volunteers
• Dose-proportional pharmacokinetics
• No significant drug-drug interactions
• Acceptable adverse event profile[@marchetti2018]

Phase 2 for Inflammatory Conditions

Prior to the PD trial, dapansutrile has been evaluated in Phase 2 trials for various inflammatory conditions including:

• Gout
• Osteoarthritis
• Cardiovascular inflammation
• Metabolic disorders

Current Phase 2 Trial (NCT07157735)

The Phase 2 clinical trial represents a critical milestone for dapansutrile in PD:

• Objective: Evaluate safety, tolerability, and efficacy of dapansutrile in PD patients
• Population: Adults with diagnosed Parkinson's disease
• Design: Randomized, double-blind, placebo-controlled
• Duration: 12-week treatment period with 4-week follow-up
• Primary endpoints: Safety and tolerability
• Secondary endpoints: Motor function scales (MDS-UPDRS), non-motor symptoms, inflammatory biomarkers

Scientific Rationale for PD Application

The NLRP3 inflammasome plays a critical role in chronic neuroinflammation observed in Parkinson's disease. In PD[@zhou2021][@greaney2022]:

Dapansutrile's anti-inflammatory mechanism directly targets this fundamental inflammatory pathway, offering the potential for disease modification rather than merely symptomatic relief.

Evidence from PD Patient Studies

Clinical studies have demonstrated elevated inflammatory markers in PD patients:

• Elevated IL-1β: Increased levels in cerebrospinal fluid and substantia nigra
• NLRP3 genetic variants: Certain polymorphisms associated with PD susceptibility
• Microglial activation: PET imaging shows increased TSPO binding indicating neuroinflammation
• Peripheral inflammation: Systemic inflammatory markers correlate with disease severity[@caldi2021]

Trial Design Details

Patient Population

The trial enrolls patients meeting criteria for Parkinson's disease diagnosis:

• Age 40-80 years
• Hoehn and Yahr stage 1-3
• On stable dopaminergic medication
• No significant cognitive impairment

Intervention and Control

• Treatment arm: Dapansutrile oral tablets at predetermined dose
• Control arm: Matching placebo
• Randomization: 2:1 ratio (dapansutrile:placebo)
• Blinding: Double-blind design

Outcome Measures

Primary Outcomes:

• Incidence and severity of adverse events
• Changes in vital signs and laboratory values

• Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores
• Non-motor symptoms questionnaire
• Inflammatory biomarker levels (IL-1β, IL-18)
• Quality of life measures

Potential Benefits and Risks

Expected Benefits

Based on preclinical data, dapansutrile may provide:

Risk Considerations

Potential risks include:

• Gastrointestinal adverse effects (nausea, diarrhea)
• Headache
• Potential interactions with other medications
• Unknown long-term safety in PD population

Cross-References and Related Content

For more detailed information, see related pages:

• [NLRP3 Inhibitors](/therapeutics/nlrp3-inhibitors)
• [NLRP3 Inhibitors for Parkinson's](/therapeutics/nlrp3-inhibitors-parkinsons)
• [Neuroinflammation in PD](/mechanisms/neuroinflammation-microglia-pathway)
• [Dapansutrile Therapeutic Profile](/therapeutics/dapansutrile-parkinsons)
• [Dapansutrile for Parkinson's Disease](/therapeutics/dapansutrile-parkinsons-disease)
• [Pyroptosis Signaling Pathway](/mechanisms/pyroptosis-signaling-pathway-neurodegeneration)
• [Microglia in Neuroinflammation](/cell-types/microglia-in-neuroinflammation)

Conclusion

The Phase 2 trial of dapansutrile (NCT07157735) represents an important step toward developing disease-modifying therapies for Parkinson's disease. By targeting the NLRP3 inflammasome, a central mechanism of neuroinflammation, dapansutrile offers a novel approach that addresses the underlying pathophysiology of PD rather than merely alleviating symptoms.

The strong preclinical evidence demonstrating neuroprotection in multiple PD models, combined with the established safety profile from prior clinical trials, provides a solid foundation for this clinical investigation. Successful results would represent a significant advance in the treatment of Parkinson's disease and validate NLRP3 as a therapeutic target in neurodegeneration.

Comparison with Other NLRP3 Inhibitors

The NLRP3 inflammasome has attracted significant attention as a therapeutic target, leading to the development of multiple inhibitors[@zhang2023]. Understanding how dapansutrile compares with other candidates provides context for its clinical potential.

MCC950

MCC950 was the most extensively studied preclinical NLRP3 inhibitor, demonstrating potent neuroprotection in PD models. However, clinical development was discontinued due to hepatotoxicity observed in Phase 1 trials. This safety concern highlighted the challenges of targeting NLRP3 systemically while maintaining an acceptable therapeutic window.

Inzomelid

Inzomelid is another NLRP3 inhibitor that has entered clinical trials for inflammatory conditions. Like dapansutrile, it offers selective NLRP3 inhibition with a favorable safety profile. However, inzomelid has not yet been evaluated in PD clinical trials.

Dapansutrile's Advantages

Dapansutrile offers several advantages for PD treatment:

Future Directions and Broader Applications

Multiple System Atrophy

Beyond Parkinson's disease, dapansutrile holds promise for other neurodegenerative disorders characterized by neuroinflammation. Multiple System Atrophy (MSA) shares pathological features with PD, including α-synuclein aggregation and neuroinflammation. Preclinical studies have demonstrated dapansutrile's efficacy in MSA models[@mechanisms/nlrp3-inflammasome].

Alzheimer's Disease

The NLRP3 inflammasome also plays a role in Alzheimer's disease pathophysiology. Dapansutrile has demonstrated benefits in AD mouse models, reducing amyloid pathology and improving cognitive function. Future clinical trials in AD may be considered based on PD trial results.

Amyotrophic Lateral Sclerosis

ALS involves neuroinflammation as a component of disease pathogenesis. NLRP3 inhibition represents a potential therapeutic strategy, and dapansutrile's safety profile makes it a candidate for future ALS investigations.

Regulatory Considerations and Development Path

Orphan Drug Potential

Given the significant unmet need in Parkinson's disease and the novel mechanism of action, dapansutrile may qualify for orphan drug designation in certain jurisdictions. This status could provide regulatory incentives and accelerated approval pathways.

Adaptive Trial Design

Modern clinical trial designs allow for adaptive approaches that can optimize resource utilization and increase the likelihood of detecting efficacy signals. The NCT07157735 trial may incorporate adaptive elements such as sample size re-estimation or dose selection based on interim analyses.

Biomarker Development

The identification and validation of NLRP3-related biomarkers represents an important development pathway. Potential biomarkers include:

• IL-1β levels: Peripheral and cerebrospinal fluid cytokine measurements
• NLRP3 genetic expression: Monocyte NLRP3 mRNA levels
• Microglial activation: TSPO PET imaging
• Clinical correlates: Motor and non-motor symptom trajectories

Economic and Healthcare Implications

Disease Burden

Parkinson's disease imposes substantial economic burden on patients, families, and healthcare systems. Direct medical costs include medications, hospitalizations, and long-term care. Indirect costs arise from reduced productivity and caregiver burden. Disease-modifying therapies that slow progression could significantly reduce these economic impacts.

Healthcare Resource Utilization

Current PD management requires escalating healthcare resources as disease advances. Dopaminergic medications, deep brain stimulation, and institutional care represent significant costs. Successful neuroprotective therapy could reduce or delay these resource needs.

Patient Quality of Life

Beyond economic considerations, PD severely impacts patient quality of life. Motor disabilities limit independence, while non-motor symptoms contribute to depression, anxiety, and cognitive decline. Disease-modifying treatment would address these fundamental limitations of current therapy.

Research Gaps and Outstanding Questions

Optimal Patient Selection

Several questions remain regarding optimal patient selection for NLRP3 inhibitor therapy:

• Disease stage: Should treatment be initiated early or in established PD?
• Genetic factors: Do certain genetic backgrounds predict better response?
• Biomarker-guided selection: Can inflammatory biomarkers identify responders?
• Combination therapy: Should NLRP3 inhibitors be combined with dopaminergic therapy?

Mechanism Validation

While preclinical data strongly support NLRP3 as a therapeutic target, human validation remains incomplete:

• Target engagement: Direct confirmation of NLRP3 inhibition in human brain
• Biomarker correlation: Relationship between peripheral and central inflammation
• Disease modification: Radiographic evidence of neuroprotection

Long-term Effects

The long-term effects of NLRP3 inhibition require investigation:

• Chronic dosing safety: Extended treatment tolerability
• Immunomodulation consequences: Potential effects on infection susceptibility
• Disease trajectory: Multi-year outcome data

Conclusion and Future Outlook

The Phase 2 clinical trial of dapansutrile (NCT07157735) represents a pivotal moment in the development of NLRP3-targeted therapies for neurodegenerative diseases. This innovative approach addresses the fundamental inflammatory mechanisms that contribute to Parkinson's disease progression, offering potential for disease modification rather than purely symptomatic relief.

The strong scientific foundation supporting this trial includes:

Successful completion of this trial would not only validate dapansutrile as an effective PD therapy but also establish NLRP3 inhibition as a viable therapeutic strategy for neurodegeneration more broadly. This could catalyze further development of next-generation NLRP3 inhibitors and combination approaches targeting multiple pathological mechanisms.

The journey from preclinical discovery to clinical validation exemplifies the challenges and opportunities in neurodegenerative disease drug development. While significant obstacles remain, the dapansutrile Phase 2 trial represents meaningful progress toward addressing one of medicine's most challenging therapeutic areas. Created: 2026-03-27 Last updated: 2026-03-27